Prevnar™ 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) – Expanded indication
July 12, 2016 – Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults 18 years of age and older.
Top